688266 Suzhou Zelgen Biopharmaceuticals
- 55.64
- +1.55+2.87%
Suzhou Zelgen Biopharmaceuticals News
Zejing Pharmaceutical (688266.SH): Gicaxitinib hydrochloride tablets obtained drug clinical trial approval notice
Gelonghui, May 29丨Zejing Pharmaceutical (688266.SH) announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase II/III clinical trial of gikaxitinib hydrochloride tablets (formerly known as jacketinib hydrochloride tablets) to treat adolescents and adults aged 12 and above and patients with non-segmental vitiligo was approved.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Investors Are Less Pessimistic Than Expected
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) price-to-sales (or "P/S") ratio of 37x may look like a poor investment opportunity when you consider close to half the companies in the Biotec
Zejing Pharmaceutical (688266.SH): net loss of 279 million yuan in 2023
Gelonghui, April 19丨Zejing Pharmaceutical (688266.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 386 million yuan, an increase of 27.83% over the previous year; net profit attributable to shareholders of listed companies - 279 million yuan; basic earnings per share - 1.09 yuan.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Market Cap Dropped CN¥1.2b Last Week; Retail Investors Bore the Brunt
Key Insights Suzhou Zelgen BiopharmaceuticalsLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 13 investor
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials
Suzhou Zejing Biopharmaceutical (SHA:688266) said the National Medical Products Administration (NMPA) issued a Clinical Trial Approval for its Jacktinib Cream to treat non-segmental vitiligo, accordin
Zejing Pharmaceutical (688266.SH): Jacketinib hydrochloride cream obtained drug clinical trial approval
Zejing Pharmaceutical (688266.SH) issued an announcement. The company recently received from the State Drug Administration (hereinafter referred to as...
Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
R&D expenses continue to be invested in Zejing Pharmaceutical (688266.SH), with a net loss of 279 million yuan in 2023
Zejing Pharmaceutical (688266.SH) disclosed its 2023 annual performance report. During the reporting period, the company achieved operating income of 3...
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
The Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) share price has fared very poorly over the last month, falling by a substantial 29%. The drop over the last 30 days has capped off a toug
Zejing Pharmaceutical (688266.SH): The phase III clinical study of jacketinib tablets to treat severe alopecia areata has been completed
Gelonghui, January 29丨Zejing Pharmaceutical (688266.SH) disclosed an investor relations activity record sheet showing that the “Phase II Clinical Trial Evaluating the Safety and Efficacy of Jacketinib Hydrochloride Tablets in Treating Severe Alopecia Areata” (Plan Number: ZGJAK003) enrolled a total of 111 patients with severe alopecia areata. The participants were patients with a SALT score of at least 50%. Subjects who met the entry criteria were randomly grouped and treated with 50 mg BID, 150 mg QD, or 200 mg QD of jacketinib hydrochloride tablets, respectively. The primary efficacy endpoint of the trial was efficiency, defined as a 24-week SALT evaluation
Zejing Pharmaceutical (688266.SH): Currently, ZG006 has obtained clinical approvals from China and the US, and phase I clinical research is being carried out
Gelonghui, January 29丨Zejing Pharmaceutical (688266.SH) disclosed an investor relations activity record table showing that ZG006 is a three-specific antibody targeting CD3 and two different DLL3 epitopes. The anti-DLL3 terminal of ZG006 binds to different DLL3 epitopes on the surface of tumor cells, and the anti-CD3 terminal binds to T cells. ZG006 connects tumor cells and T cells, brings T cells closer to tumor cells, thereby using T cells to specifically kill tumor cells. DLL3 is overexpressed in small cell lung cancer and neuroendocrine cancer. About 85% of human small cell lung cancer tumors express D
Zejing Pharmaceutical (688266.SH): Expected net loss of 250 million yuan to 336 million yuan in 2023
Gelonghui, January 26丨Zejing Pharmaceutical (688266.SH) announced that according to preliminary estimates by the finance department, it is expected to achieve operating income of 365.1847 million yuan to 39,80319 million yuan in 2023, an increase of 62.8896 million yuan to 95.7269 million yuan over the same period last year, an increase of 20.80% to 31.67% over the previous year. The company expects net profit attributable to shareholders of listed companies in 2023 to be -335.701 million yuan to -25,028 million yuan, a decrease of 122.0717 million yuan to 20,749 yuan compared to the same period last year
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Market Cap Dropped CN¥686m Last Week; Retail Investors Bore the Brunt
Key Insights Suzhou Zelgen BiopharmaceuticalsLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 13 shareholder
The new drug behind Zejing Pharmaceutical's caution was approved and chose “fall into the bag for safety”
“Investor Network” Cai Jun More than 2 years later, Zejing Pharmaceutical (688266.SH, hereinafter referred to as the “Company”) has a second marketed drug. In January of this year, the company announced that it had received the “Drug Registration Certificate” from the State Drug Administration, and its self-developed recombinant human thrombin was approved for marketing. Currently, only American recombinant human thrombin Recothrom is a similar product in the world, and it has been sold overseas for many years. As an enterprise focusing on independent R&D, production and commercialization of innovative drugs, in the first three quarters of 2023, Zejing Pharmaceutical's revenue was 282 million yuan, an increase of 42.55% over the previous year; it belongs to a listed company
Zejing Pharmaceutical (688266.SH): The ban on 96.6069 million restricted shares was lifted on January 23
Gelonghui January 12丨Zejing Pharmaceutical (688266.SH) announced that the total number of shares in circulation during the current stock listing of the company is 96.6069 million shares. The current stock listing circulation date is January 23, 2024.
Zejing Pharmaceutical (688266.SH): Approval of jacketinib is currently in the normal process
Gelonghui, January 10丨Zejing Pharmaceutical (688266.SH) said on the investor interactive platform that the “Exclusive Marketing Service Agreement for Recombinant Human Thrombin” signed by the company and Yuanda Liaoning has entered into force, and the relevant payments will be made in accordance with the agreement. Jack Tini's approval is currently in the normal process. The company team continues to maintain active communication with CDE and will promptly fulfill information disclosure obligations in accordance with subsequent progress.
Zejing Pharmaceutical (688266.SH): Recombinant human thrombin approved for marketing
On January 2, Gelonghui Pharmaceutical (688266.SH) announced that it has received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the marketing application for the new drug recombinant thrombin independently developed by the company was approved to “control bleeding in adults using standard surgical hemostasis techniques (such as stitching, ligation, or electrocoagulation), which is ineffective or impracticable to promote bleeding from surgical wounds or hemostasis of capillary and venous hemorrhage”. Recombinant human thrombin is a highly specific human serine protease developed based on the company's complex recombinant protein drug and new antibody drug development and industrialization platform. It is currently the only one using recombinant gene technology in China
Zejing Pharmaceutical (688266.SH): The company has conducted a phase III clinical trial of jacktinib hydrochloride tablets to treat severe alopecia areata
Ge Longhui, December 25, 丨 Zejing Pharmaceutical (688266.SH) recently said at an analysts' meeting that in the field of autoimmune diseases, the company has carried out phase III clinical trials of jacktinib hydrochloride tablets to treat severe alopecia areata, and has completed enrollment. It is currently under observation. The development progress of this indication is at the forefront of domestic JAK inhibitors; phase III clinical trials for moderate to severe atopic dermatitis and phase III clinical trials for ankylosing spondylitis are also being accelerated. Additionally, phase II clinical trials for autoimmune related diseases such as idiopathic pulmonary fibrosis and moderate to severe plaque psoriasis
Zejing Pharmaceutical (688266.SH): ZG006 has obtained clinical approvals from China and the US, and is currently carrying out phase I clinical research in China
Gelonghui, December 25丨Zejing Pharmaceutical (688266.SH) recently stated at an analyst meeting that ZG006 is a tri-specific antibody targeting CD3 and two different DLL3 epitopes. The anti-DLL3 terminal of ZG006 binds to different DLL3 epitopes on the surface of tumor cells, and the anti-CD3 terminal binds to T cells. ZG006 connects tumor cells and T cells, brings T cells closer to tumor cells, thereby using T cells to specifically kill tumor cells. DLL3 is a high-expression target in small cell lung cancer and has been proven effective by international pharmaceutical companies. ZG006 Targeting Tumor DLL
Some Confidence Is Lacking In Suzhou Zelgen Biopharmaceuticals Co., Ltd.'s (SHSE:688266) P/S
With a price-to-sales (or "P/S") ratio of 34.2x Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHSE:688266) may be sending very bearish signals at the moment, given that almost half of all the Biotechs c
Analysis
Price Target
No Data
